NCT04546256View on ClinicalTrials.gov

A Pilot Bioequivalence Study Between Fluticasone Propionate 500 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 500/50 Inhalation Powder/GSK in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 1, 2020

Primary Completion Date

September 25, 2020

Study Completion Date

December 31, 2020

Conditions

Bioequivalence

Interventions

DRUG

Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg/Respirent

2 inhalations of Test and Reference product in each study period

DRUG

ADVAIR DISKUS® 500/50

2 inhalations of Test and Reference product in each study period

Trial Locations (1)

41100

BECRO Clinical Facility, Larissa

All Listed Sponsors

collaborator

Becro Ltd.

INDUSTRY

lead

Respirent Pharmaceuticals Co Ltd.

INDUSTRY

NCT04546256 - A Pilot Bioequivalence Study Between Fluticasone Propionate 500 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 500/50 Inhalation Powder/GSK in Healthy Volunteers | Biotech Hunter | Biotech Hunter